Prolonged clinical response with regorafenib administered as second-line therapy in an elderly patient suffering from peritoneal carcinomatosis of colon cancer

References

• International Agency for Research on Cancer [Internet]. Cancers fact sheets: colorectal cancer [cited 2017 Feb 15]. Available from: http://gco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-6.pdf.
   Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–4705.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392–2401.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–3506.
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–1765.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–1034.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37.
   PubMed Web of Science ®Google Scholar
• Rosati G, Aprile G, Poletto E, Avallone A. An update on the management of metastatic colorectal cancer in the elderly. Colorect Cancer. 2014;3(5):451–463.
   Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R, Yau TCC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–629.
   PubMed Web of Science ®Google Scholar
• ) Glehen O, Osinsky D, Beaujard AC, Gilly FN. Natural history of peritoneal carcinomatosis from non-gynecologic malignancies. Surg Oncol Clin N Am. 2003;12(3):729–739.
   PubMedGoogle Scholar
• Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–363.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374.
   PubMedGoogle Scholar
• Ducreux M, Petersen LN, Öhler L, Bergamo F, Metges J-P, de Groot JW, Wang J-Y, García Paredes B, Dochy E, Fiala-Buskies S, et al. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Eur J Cancer. 2019;123:146–154.
   PubMed Web of Science ®Google Scholar
• Kopeckova K, Buchler T, Bortlicek Z, Hejduk K, Chloupkova R, Melichar B, Pokorna P, Tomasek J, Linke Z, Petruzelka L, et al. Regorafenib in the real-life clinical practice: data from the Czech Registry. Target Oncol. 2017;12(1):89–95.
   PubMed Web of Science ®Google Scholar
• Ma C-J, Huang C-W, Chang T-K, Tsai H-L, Su W-C, Yeh Y-S, Chen P-J, Wang J-Y. Oncologic outcomes in metastatic colorectal cancer with regorafenib with FOLFIRI as a third- or fourth-line setting. Transl Oncol. 2019;12(3):502–512.
   PubMed Web of Science ®Google Scholar
• Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, Dourthe L-M, Etienne P-L, Mineur L, Clisant S, et al. Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16(1):518.
   PubMedGoogle Scholar
• Yoshino K, Manaka D, Kudo R, Kanai S, Mitsuoka E, Kanto S, Hamasu S, Konishi S, Nishitai R. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report. J Med Case Rep. 2017;11(1):227
   PubMedGoogle Scholar
• Roberto M, Falcone R, Mazzuca F, Archibugi L, Castaldi N, Botticelli A, Osti MF, Marchetti P. The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: clinical case report of a long-responder patient treated with regorafenib beyond progression . Medicine (Baltimore)). 2017;96(48):e9023.
   PubMed Web of Science ®Google Scholar
• Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, et al. Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature . Oncotarget. 2017;8(34):57882–57888.
   PubMedGoogle Scholar
• Callebout E, Ribeiro SM, Laurent S, De Man M, Ferdinande L, Claes KBM, Van der Meulen J, Geboes KP. Long term response on regorafenib in non-V600E BRAF mutated colon cancer: a case report . BMC Cancer. 2019;19(1):567.
   PubMedGoogle Scholar
• Amram ML, Montet X, Roth AD. Long-term survival with regorafenib in KRAS-mutated metastatic rectal cancer. Case Rep Oncol. 2017;10(3):1029–1034.
   PubMed Web of Science ®Google Scholar
• Brunetti O, Calabrese A, Palermo L, Solimando AG, Argentiero A. Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: case report and literature review. Clin Case Rep. 2019;7(12):2379–2383.
   PubMed Web of Science ®Google Scholar
• Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013;24(6):1560–1567.
   PubMed Web of Science ®Google Scholar
• Argilés G, Saunders MP, Rivera F, Sobrero A, Benson A, Guillén Ponce C, Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, et al. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. Eur J Cancer. 2015;51(8):942–949.
   PubMed Web of Science ®Google Scholar
• García-Alfonso P, Benavides M, Falcó E, Muñoz A, Gómez A, Sastre J, Rivera F, Montagut C, Salgado M, López-Ladrón A, et al. Single-agent regorafenib in metastatic colorectal cancer patients with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab (PREVIUM Trial). Oncologist. 2018;23(11):1271.
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, et al. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. 2018;124(15):3118–3126.
   PubMed Web of Science ®Google Scholar
• Ruff P, Van Cutsem E, Lakomy R, Prausova J, van Hazel GA, Moiseyenko VM, Soussan-Lazard K, Dochy E, Magherini E, Macarulla T, et al. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: an age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol. 2018;9(1):32–39.
   PubMed Web of Science ®Google Scholar